Onkure Therapeutics, INC Form 4 insider transactions

OnKure Therapeutics' CFO, Jason A. Leverone, sold 302 shares of Class A Common Stock to cover tax withholding obligations related to RSU vesting.

OnKure Therapeutics Director Edward T. Mathers acquired 4,125 shares of Class A Common Stock through vested restricted stock units as compensation, increasing his direct beneficial ownership to 11,399 shares.

OnKure Therapeutics Director Isaac Manke acquired 5,545 shares of Class A Common Stock through vested restricted stock units, bringing his total beneficial ownership to 15,325 shares.

OnKure Therapeutics CEO Nicholas Saccomano sold 88 shares of Class A Common Stock on September 22, 2025, to cover tax withholding obligations related to RSU vesting.

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, sold 303 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

OnKure Therapeutics, Inc. Director Edward T Mathers is scheduled to acquire 4,694 shares of Class A Common Stock through a pre-planned restricted stock unit grant on June 30, 2025, which will bring his total direct beneficial ownership to 7,274 shares.

OnKure Therapeutics, Inc. Director Isaac Manke has acquired 6,311 shares of Class A Common Stock through the vesting of restricted stock units, part of the company's director compensation policy.

OnKure Therapeutics, Inc. President and CEO, Nicholas A. Saccomano, sold 88 shares of Class A Common Stock to satisfy tax withholding obligations related to RSU vesting.

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, sold 303 shares of Class A Common Stock on June 23, 2025, at a weighted average price of $2.3842 to cover tax withholding obligations related to RSU vesting.

OnKure Therapeutics, Inc. Director Edward T. Mathers has acquired 7,650 stock options with an exercise price of $2.44, signaling continued alignment with shareholder interests.

OnKure Therapeutics, Inc. Director Andrew John Phillips was granted 7,650 stock options with an exercise price of $2.44, vesting based on continued service.

OnKure Therapeutics, Inc. Director Isaac Manke has acquired 7,650 stock options with an exercise price of $2.44, vesting by May 28, 2026, or the next annual meeting.

OnKure Therapeutics, Inc. Director Valerie Malyvanh Jansen reported the acquisition of 7,650 stock options with an exercise price of $2.44, vesting on the earlier of May 28, 2026, or the day prior to the next annual meeting.

OnKure Therapeutics, Inc. director Michael G. Grey was granted 7,650 stock options with an exercise price of $2.44, vesting by May 28, 2026, or the next annual meeting.

OnKure Therapeutics, Inc. Director R Michael Carruthers acquired 7,650 stock options with an exercise price of $2.44, vesting by May 28, 2026, or the next annual meeting.

Cormorant Asset Management, along with related entities and Bihua Chen, reported the sale of 1,813,439 shares of OnKure Therapeutics Class A Common Stock at an average price of $1.8545 per share.

Acorn Bioventures, L.P. reports acquiring additional shares of OnKure Therapeutics, Inc. at $1.85 per share, increasing its beneficial ownership.

Cormorant Asset Management reports a transaction involving the disposal of shares in OnKure Therapeutics, while maintaining significant beneficial ownership.

Nicholas A. Saccomano, CEO of OnKure Therapeutics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Jason A. Leverone, CFO of OnKure Therapeutics, sold shares of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units.

Director Edward T. Mathers acquired 2,580 shares of OnKure Therapeutics Class A Common Stock through fully vested restricted stock units (RSUs) in lieu of a quarterly cash retainer.

Director Isaac Manke acquired 3,469 shares of OnKure Therapeutics Class A Common Stock in lieu of a quarterly cash retainer.

OnKure Therapeutics CEO Nicholas Saccomano was granted 130,000 stock options on January 27, 2025, which vest monthly over four years.

OnKure Therapeutics' Chief Financial Officer, Jason A. Leverone, was granted 65,000 stock options on January 27, 2025.

OnKure Therapeutics' Chief Scientific Officer, Dylan Hartley, was granted 45,000 stock options on January 27, 2025, which vest monthly starting February 27, 2025.

OnKure Therapeutics' Chief Medical Officer, Samuel Agresta, was granted 45,000 stock options on January 27, 2025, which vest monthly over four years.

Braden Michael Leonard, a former 10% owner of RPHM, reports changes in beneficial ownership of OnKure Therapeutics stock following the merger with Reneo Pharmaceuticals.

Following the merger of OnKure, Inc. with Reneo Pharmaceuticals, Inc., CEO Nicholas Saccomano reports changes in beneficial ownership of Class A Common Stock and derivative securities.

Director Andrew John Phillips acquires stock options in OnKure Therapeutics.

Director Edward T. Mathers acquires 15,300 stock options in OnKure Therapeutics, Inc.